BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35235931)

  • 41. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
    Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.
    Zhang W; Shen H; Zhang Y; Wang W; Hu S; Zou D; Zhou D
    Cancer Med; 2019 May; 8(5):2104-2113. PubMed ID: 30969023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology.
    Muraro E; Romanò R; Fanetti G; Vaccher E; Turturici I; Lupato V; La Torre FB; Polesel J; Fratta E; Giacomarra V; Franchin G; Steffan A; Spina M; Alfieri S
    Crit Rev Oncol Hematol; 2022 Jul; 175():103707. PubMed ID: 35569724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
    Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
    Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
    Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases.
    Zhan HQ; Li XQ; Zhu XZ; Lu HF; Zhou XY; Chen Y
    J Clin Pathol; 2011 Apr; 64(4):319-24. PubMed ID: 21330314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Programmed death-1
    Singh A; Mohan A; Dey AB; Mitra DK
    Clin Exp Immunol; 2017 Feb; 187(2):269-283. PubMed ID: 27665733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.